Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
LY03015 / Luye Group
NCT05238701: A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in Healthy Subjects	Completed	1	104	RoW	LPM3770164 sustained release tablet, LY03015, LPM3770164 sustained release tablet simulant, LY03015 simulant	Luye Pharma Group Ltd.	Huntington Disease, Tardive Dyskinesia	11/23	11/23
NCT06216054: Safety, Tolerability and Pharmacokinetic of Multiple-ascending Doses of LPM3770164 in Healthy Subjects	Recruiting	1	48	RoW	LPM3770164 sustained release tablet, LPM3770164 sustained release tablet simulant	Luye Pharma Group Ltd.	Tardive Dyskinesia, Huntington Disease	08/24	08/24
NCT06474650: Effect of Food on the Pharmacokinetics of LPM3770164 Sustained-release Tablets	Not yet recruiting	1	16	RoW	LPM3770164 sustained release tablet, LY03015	Luye Pharma Group Ltd.	Huntington Disease, Tardive Dyskinesia	09/24	10/24